Clal Insurance Enterprises Holdings Ltd Boosts Stake in DexCom, Inc. $DXCM

Clal Insurance Enterprises Holdings Ltd increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 234.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 20,051 shares of the medical device company’s stock after acquiring an additional 14,051 shares during the quarter. Clal Insurance Enterprises Holdings Ltd’s holdings in DexCom were worth $1,331,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. CVA Family Office LLC raised its position in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC purchased a new position in DexCom in the 4th quarter worth $32,000. ORG Partners LLC raised its position in DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. Spire Wealth Management raised its position in DexCom by 113.8% in the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the period. Finally, Aventura Private Wealth LLC purchased a new position in DexCom in the 4th quarter worth $43,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on DXCM shares. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Wells Fargo & Company decreased their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Benchmark started coverage on shares of DexCom in a research report on Monday, May 11th. They issued a “buy” rating and a $77.00 target price on the stock. Barclays reiterated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $84.29.

DexCom Price Performance

Shares of DexCom stock opened at $75.37 on Friday. The firm has a market cap of $29.08 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 1.18 and a beta of 1.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company’s fifty day simple moving average is $66.13 and its two-hundred day simple moving average is $67.56.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. As a group, equities analysts expect that DexCom, Inc. will post 2.58 EPS for the current year.

Insider Activity

In other news, EVP Jon Coleman sold 4,911 shares of DexCom stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. The trade was a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. The trade was a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 42,694 shares of company stock worth $3,029,267 in the last quarter. Insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.